Published in PLoS One on August 06, 2015
Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov (2006) 15.21
New use of BCG for recombinant vaccines. Nature (1991) 14.40
How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov (2010) 14.09
inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science (1994) 11.22
Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother (1997) 9.16
Controlling gene expression in mycobacteria with anhydrotetracycline and Tet repressor. Nucleic Acids Res (2005) 4.00
Challenges of antibacterial discovery. Clin Microbiol Rev (2011) 3.94
Quality and position of the three lac operators of E. coli define efficiency of repression. EMBO J (1994) 2.90
In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice. Nat Med (2007) 2.76
Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for Mycobacterium tuberculosis to establish and maintain infection. Proc Natl Acad Sci U S A (2010) 2.62
Recombinant protein expression in Escherichia coli: advances and challenges. Front Microbiol (2014) 2.40
The lac operator-repressor system is functional in the mouse. Genes Dev (2001) 2.24
Discovery of a small molecule that inhibits cell division by blocking FtsZ, a novel therapeutic target of antibiotics. J Biol Chem (2003) 1.75
Principles of early drug discovery. Br J Pharmacol (2011) 1.68
An array of target-specific screening strains for antibacterial discovery. Nat Biotechnol (2002) 1.56
Regulatable arabinose-inducible gene expression system with consistent control in all cells of a culture. J Bacteriol (2000) 1.56
Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol (2012) 1.55
Regulated gene expression in Staphylococcus aureus for identifying conditional lethal phenotypes and antibiotic mode of action. Gene (2000) 1.55
Depletion of antibiotic targets has widely varying effects on growth. Proc Natl Acad Sci U S A (2011) 1.54
Use of a tetracycline-inducible system for conditional expression in Mycobacterium tuberculosis and Mycobacterium smegmatis. Appl Environ Microbiol (2005) 1.45
Conditional expression of Mycobacterium smegmatis ftsZ, an essential cell division gene. Microbiology (2003) 1.40
Pristinamycin-inducible gene regulation in mycobacteria. J Biotechnol (2009) 1.28
Chemical genetic identification of peptidoglycan inhibitors potentiating carbapenem activity against methicillin-resistant Staphylococcus aureus. Chem Biol (2009) 1.23
lac repressor mutants with double or triple exchanges in the recognition helix bind specifically to lac operator variants with multiple exchanges. EMBO J (1989) 1.18
Simultaneous analysis of multiple Mycobacterium tuberculosis knockdown mutants in vitro and in vivo. PLoS One (2010) 1.14
Development of a repressible mycobacterial promoter system based on two transcriptional repressors. Nucleic Acids Res (2010) 1.13
Identification of in vitro folding conditions for procathepsin S and cathepsin S using fractional factorial screens. Protein Expr Purif (2002) 1.09
Staphylococcus aureus TargetArray: comprehensive differential essential gene expression as a mechanistic tool to profile antibacterials. Antimicrob Agents Chemother (2010) 1.08
Delineating bacteriostatic and bactericidal targets in mycobacteria using IPTG inducible antisense expression. PLoS One (2009) 1.07
Controlling gene expression in mycobacteria. Future Microbiol (2006) 1.05
The metabolic activity of Mycobacterium tuberculosis, assessed by use of a novel inducible GFP expression system, correlates with its capacity to inhibit phagosomal maturation and acidification in human macrophages. Mol Microbiol (2008) 1.02
A riboswitch-based inducible gene expression system for mycobacteria. PLoS One (2012) 0.99
Assessing the essentiality of the decaprenyl-phospho-d-arabinofuranose pathway in Mycobacterium tuberculosis using conditional mutants. Mol Microbiol (2014) 0.94
HemZ is essential for heme biosynthesis in Mycobacterium tuberculosis. Tuberculosis (Edinb) (2005) 0.94
Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis. J Med Chem (2013) 0.88
Novel antibacterials: a genomics approach to drug discovery. Curr Drug Targets Infect Disord (2002) 0.88
The phosphatidyl-myo-inositol mannosyltransferase PimA is essential for Mycobacterium tuberculosis growth in vitro and in vivo. J Bacteriol (2014) 0.85
Towards establishing a method to screen for inhibitors of essential genes in mycobacteria: evaluation of the acetamidase promoter. Int J Antimicrob Agents (2006) 0.85
Drug target validation: Hitting the target. Nature (2003) 0.84
Genetic and chemical validation identifies Mycobacterium tuberculosis topoisomerase I as an attractive anti-tubercular target. Tuberculosis (Edinb) (2015) 0.84
In vitro and in vivo validation of ligA and tarI as essential targets in Staphylococcus aureus. Antimicrob Agents Chemother (2008) 0.84
High-throughput screening of RNA polymerase inhibitors using a fluorescent UTP analog. J Biomol Screen (2006) 0.84
Essentiality and functional analysis of type I and type III pantothenate kinases of Mycobacterium tuberculosis. Microbiology (2010) 0.83
LC-MS based assay to measure intracellular compound levels in Mycobacterium smegmatis: linking compound levels to cellular potency. J Microbiol Methods (2013) 0.82
Target validation in mice by constitutive and conditional RNAi. Methods Mol Biol (2013) 0.80
Regulated expression of the Escherichia coli lepB gene as a tool for cellular testing of antimicrobial compounds that inhibit signal peptidase I in vitro. Antimicrob Agents Chemother (2002) 0.79
Target validation: A door to drug discovery. Drug Discov Ther (2007) 0.77